Citations

Clear

4847 citation(s) found for "Yu, Eric".

Antigen-mediated regulation in monoclonal gammopathies and myeloma
Nair, Shiny , Sng, Joel , Boddupalli, Chandra Sekhar , Seckinger, Anja , Chesi, Marta , Fulciniti, Mariateresa , Rauniyar, Navin , Parker, Terri L., Munshi, Nikhil C. , Sexton, Rachael, Barlogie, Bart , Orlowski, Robert Z. , Bergsagel, Leif, Hose, Dirk , Meffre, Eric , Dhodapkar, Madhav V. , Bergsagel, P. Leif , Bergsagel, P. Leif , Orlowski, Robert Z. , Zhang, Lin, Lopez, Michael A. , Neparidze, Natalia , Flavell, Richard A. , Mistry, Pramod K. , Hose, Dirk

Mayo Clinic

JCI Insight | April 18, 2018 | Volume: 3 | Issue: 8 | Pages: No page available

10.1172/jci.insight.98259 | PMID 29669929 Get It

A role for antigen-driven stimulation has been proposed in the pathogenesis of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) based largely on the binding properties of monoclonal Ig. However, insights into antigen binding to clonal B cell receptors and in vivo responsiveness of the malignant clone to antigen-mediated stimulation are needed to understand the role of antigenic stimulation in tumor growth. Lysolipid-reactive clonal Ig were detected in Gaucher disease (GD) and some sporadic gammopathies. Here, we show that recombinant Ig (rIg) cloned from sort-purified single tumor cells from lipid-reactive sporadic and GD-associated gammopathy specifically bound lysolipids. Liposome sedimentation and binding assays confirmed specific interaction of lipid-reactive monoclonal Ig with lysolipids. The clonal nature of lysolipid-binding Ig was validated by protein sequencing. Gene expression profiling and cytogenetic analyses from 2 patient cohorts showed enrichment of nonhyperdiploid tumors in lipid-reactive patients. In vivo antigen-mediated stimulation led to an increase in clonal Ig and plasma cells (PCs) in GD gammopathy and also reactivated previously suppressed antigenically related nonclonal PCs. These data support a model wherein antigenic stimulation mediates an initial polyclonal phase, followed by evolution of monoclonal tumors enriched in nonhyperdiploid genomes, responsive to underlying antigen. Targeting underlying antigens may therefore prevent clinical MM.
A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy
Bachy, Emmanuel , Habermann, Thomas M., Gelas‐Dore, Bénédicte, Estell, Jane, Neste, Éric Van Den, Bouabdallah, Réda, Gyan, Emmanuel , Bargay, Joan , Slager, Susan L., Silva, María Gomes da , Fitoussi, Olivier , Intragumtornchai, Tanin , Ansell, Stephen M., Lamy, T. , Dartigues, Peggy , Link, Brian K. , Seymour, John F., Salles, Gilles , Link, Brian K , Gyan, Emmanuel , Salles, Gilles A , Maurer, Matthew J. , Habermann, Thomas M. , Maucort‐Boulch, Delphine , Feldman, Andrew L. , Delmer, Alain , Slager, Susan L. , Belada, David , Maisonneuve, Hervé , Ansell, Stephen M. , Cerhan, James R. , Bachy, Emmanuel

Mayo Clinic

Blood | April 17, 2018 | Volume: 132 | Issue: 1 | Pages: 49-58

10.1182/blood-2017-11-816405 | PMID 29666118 Get It

Key Points In FL, no prognostic index has been built based solely on a large cohort of patients treated with initial immunochemotherapy. The PRIMA-PI is a simplified index based on β2m and bone marrow involvement for patients treated with immunochemotherapy.
Predictors of 1-year mortality after transcatheter aortic valve replacement
Greason, Kevin L. , Eleid, Mackram F. , Williamson, Eric E. , Sandhu, Gurpreet S. , Holmes, David R. , King, Katherine S. , Nkomo, Vuyisile T.

Mayo Clinic

Journal of Cardiac Surgery | April 14, 2018 | Volume: 33 | Issue: 5 | Pages: 243-249

10.1111/jocs.13574 | PMID 29654615 Get It

Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry
Fudim, Marat , Liu, Peter R., Shrader, Peter, Blanco, Rosalia , Kowey, Peter R. , Go, Alan S. , Thomas, Laine , Piccini, Jonathan P. , Allen, Larry A. , Fonarow, Gregg C. , Gersh, Bernard J. , Mahaffey, Kenneth W. , Hylek, Elaine M. , Peterson, Eric D.

Mayo Clinic

Journal of the American Heart Association | April 13, 2018 | Volume: 7 | Issue: 8 | Pages: No page available

10.1161/jaha.117.007987 | PMID 29654203 Get It

Background Mineralocorticoid receptor antagonist ( MRA ) therapy may be beneficial to patients with atrial fibrillation ( AF ), but little is known about their use in patients with AF and subsequent outcomes. Methods and Results In order to better understand MRA use and subsequent outcomes, we performed a retrospective cohort study of the contemporary ORBIT ‐ AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry. AF progression and cardiovascular outcomes were compared using propensity‐matched Cox proportional hazards modeling according to MRA use at baseline and new MRA use at follow‐up versus patients with no MRA use. Among 7012 patients with nonpermanent AF , 320 patients were taking MRA at enrollment, and 416 patients initiated MRA use during follow‐up. The mean patient age was 72.5 years, 56.3% were men, and 70.4% had paroxysmal AF . Among all patients taking MRAs, 434 (59.0%) had heart failure, 655 (89.0%) had hypertension, and 380 (51.6%) had both. After adjustment, new MRA use was not associated with reduced AF progression (hazard ratio, 1.18; 95% confidence interval, 0.88–1.58; P =0.27) but showed a trend towards lower risk of stroke, transient ischemic attack, or systemic embolism (hazard ratio, 0.17; 95% confidence interval, 0.02–1.23; P =0.08). Results were similar for a comparison of new MRA users and baseline MRA users compared with nonusers. Conclusions In community‐based outpatients with AF , the majority of MRA use was for heart failure and hypertension. MRA use also trended towards lower adjusted stroke risk. Future studies should test the hypothesis that MRA use may decrease the risk of stroke in patients with AF .
Influence of Body Position on Shoulder and Trunk Muscle Activation During Resisted Isometric Shoulder External Rotation
Dueffert, Lucas G., Postma, Jaclyn L., Vogler, Eric T., Walsh, Amy J., Hollman, John H. , Hollman, John , Krause, David A.

Mayo Clinic

Sports Health: A Multidisciplinary Approach | April 12, 2018 | Volume: 10 | Issue: 4 | Pages: 355-360

10.1177/1941738118769845 | PMID 29648933 Get It

Background: External rotation (ER) strengthening of the shoulder is an integral component of rehabilitative and preventative programs for overhead athletes. A variety of shoulder ER strengthening exercises are reported, including those intended to integrate the core musculature. The purpose of this study was to examine ER torque and electromyographic (EMG) activation of shoulder and trunk muscles while performing resisted isometric shoulder ER in 3 positions (standing, side lying, and side plank). Hypothesis: Significantly greater force and shoulder muscle activation would be generated while side lying given the inherent stability of the position, and greater trunk muscle activation would be generated in the less stable plank position. Study Design: Quasi-experimental repeated-measures study. Level of Evidence: Level 5. Methods: A convenience sample of 25 healthy overhead recreational athletes (9 men, 16 women) participated in this study. EMG electrodes were placed on the infraspinatus, posterior deltoid, middle trapezius, multifidi, internal obliques, and external obliques. EMG signals were normalized to a maximal isometric contraction. Participants performed resisted isometric ER in standing, side-lying, and side plank positions. Results were analyzed using a repeated-measures analysis of variance with post hoc Bonferroni corrections (α = 0.05). Results: There was no significant difference in ER torque between positions (α = 0.05). A significant difference in EMG activity of shoulder and trunk musculature between positions was found in 7 of the 8 muscles monitored. Significantly greater EMG activity in the infraspinatus, middle trapezius, and the nondominant external and internal obliques was found in the side plank position as compared with standing and side lying. Conclusion: While there was no difference in ER torque between the 3 exercise positions, EMG activity of the shoulder and trunk muscles was dependent on body position. Clinical Relevance: If a clinician is seeking to integrate trunk muscle activation while performing shoulder ER strengthening, the side plank position is preferred as compared with standing or side lying.
The State of US Health, 1990-2016
Collaborators, The US Burden of Disease, Mokdad, Ali H. , Ballestros, Katherine, Echko, Michelle, Glenn, Scott , Olsen, Helen Elizabeth , Mullany, Erin C, Lee, Alex , Khan, Abdur Rahman , Ahmadi, Alireza , Ferrari, Alize J , Kasaeian, Amir , Werdecker, Andrea , Carter, Austin , Zipkin, Ben, Sartorius, Benn , Serdar, Berrin , Sykes, Bryan L. , Troeger, Chris, Fitzmaurice, Christina , Rehm, Colin D. , Santomauro, Damian , Kim, Daniel , Colombara, Danny V. , Schwebel, David C. , Tsoi, Derrick, Nichols, Emma , Oren, Eyal , Charlson, Fiona , Patton, George , Roth, Gregory A. , Kyu, Hmwe Hmwe , Erskine, Holly E , Huang, Hsiang , Martopullo, Ira , Nachega, Jean B. , Sanabria, Juan , Tabb, Karen M. , Krohn, Kristopher J, Cornaby, Leslie, Moses, Mark , Farvid, Maryam S. , Griswold, Max , Criqui, Michael H, Bell, Michelle L. , Nguyen, Minh , Wallin, Mitch, Mirarefin, Mojde, Younis, Mustafa Z , Fullman, Nancy , Liu, Patrick , Briant, Paul Svitil, Gona, Philimon , Havmöller, Rasmus, Kimokoti, Ruth W , Hay, Simon I , Yadgir, Simon , Biryukov, Stan, Vollset, Stein Emil, Alam, Shazia , Frank, Tahvi , Farid, Talha, Miller, Ted R. , Vos, Theo , Bärnighausen, Till , Gebrehiwot, Tsegaye, Yano, Yuichiro , Al‐Aly, Ziyad , Mehari, Alem , Handal, Alexis J. , Kandel, Amit , Anderson, Benjamin O. , Biroscak, Brian J. , Dorsey, E. Ray, Ding, Eric L. , Park, Eun‐Kee , Wagner, Gregory R. , Chen, Honglei , Sunshine, Jacob E. , Khubchandani, Jagdish , Leasher, Janet L , Leung, Janni , Unützer, Jürgen , Cahill, Leah E. , Cooper, Leslie T. , Bräuer, Michael , Breitborde, Nicholas J. K. , Topór-Mądry, Roman , Soneji, Samir , Stranges, Saverio , James, Spencer L , Amrock, Stephen M. , Jayaraman, Sudha , Skirbekk, Vegard , Kinfu, Yohannes , Bhutta, Zulfiqar A , Murray, Christopher J L , Topór‐Mądry, Roman , Bell, Max , Cooper, Leslie T , Collaborators, The US Burden of Disease, Kolte, Dhaval , Nsoesie, Elaine Okanyene , Hosgood, H. Dean, Whiteford, Harvey , Singh, Jasvinder A. , Abbas, Kaja , Ong, Sok King , Degenhardt, Louisa J , Qorbani, Mostafa , Leung, Ricky , Bazargan‐Hejazi, Shahrzad , Vollset, Stein Emil, Mozaffarian, Dariush , Hu, Guoqing , Salomon, Joshua A. , Horino, Masako , Hotez, Peter Jay , Patel, Tejas Kamleshbhai , Akinyemiju, Tomi , Jonas, Jost B , Oren, Eyal

Mayo Clinic

JAMA | April 10, 2018 | Volume: 319 | Issue: 14 | Pages: 1444

10.1001/jama.2018.0158 | PMID 29634829 Get It

HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome
Natesampillai, Sekar, Cummins, Nathan W. , Nie, Zilin , Sampath, Rahul , Baker, Jason V. , Henry, Keith , Pinzone, Marilia Rita , O’Doherty, Una , Bren, Gary D., Katzmann, David J. , Badley, Andrew D. , Polley, Eric C. , Cummins, Nathan W , Badley, Andrew D , O’Doherty, Una

Mayo Clinic

Journal of Virology | April 10, 2018 | Volume: 92 | Issue: 13 | Pages: No page available

10.1128/jvi.00037-18 | PMID 29643240 Get It

ABSTRACT HIV protease is known to cause cell death, which is dependent upon cleavage of procaspase 8. HIV protease cleavage of procaspase 8 generates Casp8p41, which directly binds Bak with nanomolar affinity, causing Bak activation and consequent cell death. Casp8p41 can also bind Bcl2 with nanomolar affinity, in which case cell death is averted. Central memory CD4 T cells express high levels of Bcl2, possibly explaining why those cells do not die when they reactivate HIV. Here, we determine that the Casp8p41-Bcl2 complex is polyubiquitinated and degraded by the proteasome. Ixazomib, a proteasome inhibitor in clinical use, blocks this pathway, increasing the abundance of Casp8p41 and causing more cells to die in a Casp8p41-dependent manner. IMPORTANCE The Casp8p41 pathway of cell death is unique to HIV-infected cells yet is blocked by Bcl2. Once bound by Bcl2, Casp8p41 is polyubiquitinated and degraded by the proteasome. Proteasome inhibition blocks degradation of Casp8p41, increasing Casp8p41 levels and causing more HIV-infected cells to die.
Volumetric laser endomicroscopy interpretation and feature analysis in dysplastic Barrett's esophagus
Kamboj, Amrit K. , Wolfsen, Herbert C. , Trindade, Arvind J. , Ganguly, Eric K. , Otaki, Fouad , Chan, Daniel K. , Zakko, Liam , Visrodia, Kavel , Lutzke, Lori S., Wang, Kenneth K, Leggett, Cadman L. , Kahn, Allon , Trindade, Arvind J , Chan, Daniel, Lutzke, Lori, Leggett, Cadman L , Otaki, Fouad

Mayo Clinic

Journal of Gastroenterology and Hepatology | April 10, 2018 | Volume: 33 | Issue: 10 | Pages: 1761-1765

10.1111/jgh.14153 | PMID 29633412 Get It

AbstractBackground and AimVolumetric laser endomicroscopy (VLE) is used to identify Barrett's esophagus (BE) dysplasia. Selection of a dysplastic region of interest (ROI) can be challenging due to feature variability across a large amount of data. The degree of agreement among VLE users in selecting a ROI has not been studied.MethodsHigh‐definition videos that divided a VLE scan from 18 patients with biopsy‐proven BE dysplasia into 1‐cm segments were reviewed using a four‐quadrant grid superimposed for systematic interpretation. VLE scans were selected based on image quality and appropriate visualization of BE epithelium. Four experienced VLE users rated each quadrant as dysplastic or non‐dysplastic. For quadrants rated as dysplastic, reviewers selected a single timeframe with representative features. A high‐degree of agreement among reviewers was defined as ≥75% agreement on the quadrant diagnosis and ≥50% agreement on selected timeframe (±2 s).ResultsThirty‐one videos, each 32 s in length, comprising 124 quadrants were reviewed. There was high‐agreement among reviewers in 99 (80%) quadrants, of which 68 (69%) were rated as dysplastic. Compared with quadrants rated as non‐dysplastic, ROIs of quadrants rated as dysplastic contained a higher number of epithelial glands (12.7 vs 1.2, P < 0.001) with atypical architecture (54 vs 1, P < 0.001). A statistically significant difference was observed between the signal intensity profiles of quadrants rated as dysplastic and quadrants rated as non‐dysplastic (P = 0.004).ConclusionThis study highlights that experienced VLE users can identify ROIs with high‐degree of agreement. Selected ROIs contained VLE features associated with BE dysplasia.
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable
Haeberlein, Samantha Budd , Carrillo, María C. , Hendrix, James A. , Kerchner, Geoff, Margolin, Richard , Maruff, Paul , Tong, Gary, Tome, Maria, Murray, Melissa E. , Nelson, Peter T. , Sano, Mary , Mattsson, Niklas , Sultzer, David L. , Montine, Thomas J. , Jack, Clifford R. , Kolb, Hartmuth C. , Petersen, Ronald C. , Vemuri, Prashanthi , Canniere, Megan Zoschg, Resnick, Susan M. , Romano, Gary, Harten, Argonde C. van , Bain, Lisa J. , Siemers, Eric , Jack, Clifford R , Vemuri, Prashanthi , Murray, Melissa E , Knopman, David S. , Miller, David S. , Schneider, Julie A. , Wolk, David A. , Maruff, Paul

Mayo Clinic

Alzheimer's & Dementia | April 10, 2018 | Volume: 14 | Issue: 4 | Pages: 563-575

10.1016/j.jalz.2018.03.002 | PMID 29653607 Get It

AbstractThe Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the “A, T, N System” (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be applied to clinical research and drug development. In addition, challenges and barriers to the potential adoption of this new framework will be discussed. Finally, future directions for research will be proposed.
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, Clifford R. , Bennett, David A. , Blennow, Kaj , Carrillo, María C. , Dunn, Billy , Haeberlein, Samantha Budd , Jagust, William J. , Jessen, Frank , Karlawish, Jason , Liu, Enchi , Montine, Thomas J. , Phelps, Creighton H., Rankin, Katherine P. , Scheltens, Philip , Siemers, Eric , Snyder, Heather M. , Contributors, Elliott, Cerise, Masliah, Eliezer , Ryan, Laurie, Silverberg, Nina, Bennett, David A. , Jack, Clifford R , Scheltens, Philip , Holtzman, David M. , Molinuevo, José Luís , Rowe, Christopher Cleon , Sperling, Reisa Anne , Contributors

Mayo Clinic

Alzheimer's & Dementia | April 10, 2018 | Volume: 14 | Issue: 4 | Pages: 535-562

10.1016/j.jalz.2018.02.018 | PMID 29653606 Get It

Abstract In 2011, the National Institute on Aging and Alzheimer's Association created separate diagnostic recommendations for the preclinical, mild cognitive impairment, and dementia stages of Alzheimer's disease. Scientific progress in the interim led to an initiative by the National Institute on Aging and Alzheimer's Association to update and unify the 2011 guidelines. This unifying update is labeled a “research framework” because its intended use is for observational and interventional research, not routine clinical care. In the National Institute on Aging and Alzheimer's Association Research Framework, Alzheimer's disease (AD) is defined by its underlying pathologic processes that can be documented by postmortem examination or in vivo by biomarkers. The diagnosis is not based on the clinical consequences of the disease (i.e., symptoms/signs) in this research framework, which shifts the definition of AD in living people from a syndromal to a biological construct. The research framework focuses on the diagnosis of AD with biomarkers in living persons. Biomarkers are grouped into those of β amyloid deposition, pathologic tau, and neurodegeneration [AT(N)]. This ATN classification system groups different biomarkers (imaging and biofluids) by the pathologic process each measures. The AT(N) system is flexible in that new biomarkers can be added to the three existing AT(N) groups, and new biomarker groups beyond AT(N) can be added when they become available. We focus on AD as a continuum, and cognitive staging may be accomplished using continuous measures. However, we also outline two different categorical cognitive schemes for staging the severity of cognitive impairment: a scheme using three traditional syndromal categories and a six‐stage numeric scheme. It is important to stress that this framework seeks to create a common language with which investigators can generate and test hypotheses about the interactions among different pathologic processes (denoted by biomarkers) and cognitive symptoms. We appreciate the concern that this biomarker‐based research framework has the potential to be misused. Therefore, we emphasize, first, it is premature and inappropriate to use this research framework in general medical practice. Second, this research framework should not be used to restrict alternative approaches to hypothesis testing that do not use biomarkers. There will be situations where biomarkers are not available or requiring them would be counterproductive to the specific research goals (discussed in more detail later in the document). Thus, biomarker‐based research should not be considered a template for all research into age‐related cognitive impairment and dementia; rather, it should be applied when it is fit for the purpose of the specific research goals of a study. Importantly, this framework should be examined in diverse populations. Although it is possible that β‐amyloid plaques and neurofibrillary tau deposits are not causal in AD pathogenesis, it is these abnormal protein deposits that define AD as a unique neurodegenerative disease among different disorders that can lead to dementia. We envision that defining AD as a biological construct will enable a more accurate characterization and understanding of the sequence of events that lead to cognitive impairment that is associated with AD, as well as the multifactorial etiology of dementia. This approach also will enable a more precise approach to interventional trials where specific pathways can be targeted in the disease process and in the appropriate people.